// App-Quantinova.ai

215 : The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Ankit Madan

Principal Investigators

  • Mary K Baker

  • Jori E May

  • Gurudatta Naik

  • Sejong Bae

  • Guru Sonpavde

Medical Centers

  • University of Alabama, Hoover, AL

  • UAB, Birmingham, AL

  • University of Alabama at Birmingham, Birmingham, AL

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved